Skip to content

The Effect of Light Therapy on Chronic Pain

The Effect of Light Therapy on Chronic Pain

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03677206
Enrollment
55
Registered
2018-09-19
Start date
2016-06-30
Completion date
2026-12-31
Last updated
2025-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Pain

Brief summary

Chronic pain is a major problem in the USA and the rest of the world, currently, all available pharmacological interventions carry with them significant side effects. Pain clinics are specially equipped to perform intentional pain procedures to manage pain. However, there remain groups of patients what neither benefit from pharmacological nor from interventional pain procedures. Other methods have shown only minor benefits such as hypnosis or cognitive behavioral therapy. Therefore, other techniques need to be investigated. Light therapy has been shown to have significant biological effects on humans. For example, light therapy is used to manage depression. Several clinical trials have shown that certain wavelengths of light can improve wound healing, decrease temporomandibular joint dysfunction (TMJ) pain, and decrease fear of back pain. In these trials, light was directed at the site of pain. In an attempt to better understand the effect of different wavelengths of light, pre-clinical studies were conducted using rats. The investigators have shown green and blue Light emitting diode, (LED) light produced antinociception (analgesia) and reversed neuropathic pain associated with several models of chronic pain. The analgesic effect of light was completely blocked when rats had their eyes covered, this suggests that the analgesic effects seen are mainly due to systemic effect through the visual system. Preliminary experiments on rats suggest that this effect is mediated through the endogenous opioids and cannabinoid system. The investigators believe that LED light is a safe alternative to pharmacological intervention to manage pain by stimulating the endogenous endorphin and cannabinoid systems. The investigators initial target participants with history of HIV, chemotherapy induced peripheral neuropathy and fibromyalgia. Participants will be divided into 2 groups. The first group will be a control group exposed to white LED light. The second group will be exposed to green LED light, respectively. Participants will be asked to take LED light home and will be asked to set in a dark room for 2 hours daily for 3 months with their LED light on. At the end of the 3 months trial, the investigator will assess their pain intensity, analgesic use, and overall quality of life. The investigators hypothesis is that participants exposed to green and blue light will have less use of analgesics and will have better life quality.

Detailed description

During the initial visit, the investigator will collect several pieces of data from participants that are considered part of the routine care, if you are being seen in the clinic, this information will also be used for research purposes. Initially the investigator will ask participants to provide their age, gender, work status, disability status, type of work, whether a previous pain physician has evaluated or provided treatment in the past, if there is any ongoing litigation, a detailed description of the pain (burning, electrical, shooting…etc.) and its location. If the participants are being seen in the clinic for their normal care a detailed physical examination assessing the motor strength of the upper extremities, sensation to light touch and reflexes that is part of the standard of care will be provided for the participants. The participants will be asked to give a numerical value for their pain (a scale from 0-10 where 0 is no pain and 10 is the worst pain imagined). Two questionnaires will be provided for the participants to complete which are not standard of care. The first one is the EuroQol Group (EQ-5D) which provide an over assessment of the quality of life. The second is a medication log to document their analgesics use. If the participants are being evaluated via telephone call, the same questions will be conducted, but no physical exam will be provided. The participants will be assigned to either a white, or green light group. The participants have 50% chance of being in either group. Once the participants are assigned a light group, the participants will be given a strip of Light emitting diode, (LED) light that correspond to their color group. The participants will be asked to take and use the LED strip in a dark room in their house every day for two hours to be exposed to the light, the participants will do this for 10 weeks. The study start date and the outcome assessment timeline will begin from the date of your first exposure to the assigned light. The participants will be asked to complete their weekly questionnaires and daily log, these will be given to the participants on their first clinic visit or sent to the participants if they live out of town. There will be several follow up appointments as detailed below. There is a chance the participants may be asked to cross over into a different group from the one the participants were assigned, there will we a 2 week washout period, then return to clinic for light assignment then light exposure for 10 week, similar visits as described below. For the follow up clinic visit or phone call (Week 10), data similar to the information gathered at the initial visit will be collected. The description of the pain (burning, electrical, shooting…etc.) and its location will be reviewed. A physical examination assessing for pain and sensation to light touch that is part of the standard of care will be provided for the participants. At the end of the study, the participants will be asked to return the LED strip, their logs and questionnaires. There is an optional blood draw and saliva sample collection for patients that consent to this. Blood and saliva samples will be collected at baseline and end of study, blood draws will be done to look for inflammatory mediators, increased anti inflammatory mediators and endocannabinoids. Saliva samples will be collected to check for melatonin.

Interventions

Participants will be exposed to green LED strip lights in a dark room for 2 hours a day.

Participants will be exposed to white LED strip lights in a dark room for 2 hours a day.

Sponsors

University of Arizona
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Investigator)

Intervention model description

Initially, patients will receive White LED exposure, then they will be crossed over to Green LED exposure. The patients will not be told which one is the treatment and which one is the control.

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Adults ages 18 - 80 able to understand English and comply with study protocol * Peripheral neuropathy from HIV or chemotherapy. * History of fibromyalgia * Headaches * Chronic Pain * 7-day average numeric pain score of 5/10 or greater at baseline evaluation

Exclusion criteria

* Subjects receiving remuneration for their pain treatment * Subjects that are incarcerated * Subjects unable to read English and complete assessments * Addictive behavior, severe clinical depression, or psychotic features

Design outcomes

Primary

MeasureTime frameDescription
For Chronic Painbaseline and 10 - 22 weeks, depending on study armChange in the intensity of chronic pain as measured by the Numerical Pain Scale (NPS). The NPS has a value ranging from 0 to 10 out of a maximum of 10. 0 means no pain. 10 means the most severe pain.

Secondary

MeasureTime frameDescription
Fibromyalgia Impact Questionnairebaseline and 10 - 22 weeks, depending on study armChange in Fibromyalgia Impact Questionnaire (FIQ) total score. The FIQ is a validated, self-reported measure assessing physical functioning, work status, depression, anxiety, sleep, pain, stiffness, fatigue, and well-being over the past week. Scores range from 0 to 100, with higher scores indicating greater impairment.
Headache Impact Test-6baseline and 10 - 22 weeks, depending on study armChange in Headache Impact Test-6 (HIT-6) total score from baseline to 10-22 weeks. The HIT-6 is a 6-item questionnaire designed to assess the impact of headaches on daily life, including pain severity, disability, and emotional effects over the past 4 weeks. Scores range from 36 to 78, where 36-49 indicates little or no impact, 50-55 indicates some impact, 56-59 reflects substantial impact, and 60-78 indicates severe impact requiring intervention. A higher score indicates greater headache impact.
EQ-5D-5Lbaseline and 10 - 22 weeks, depending on study armChange in health-related quality of life as measured by the EQ-5D-5L. The EQ-5D-5L is a standardized, patient-reported outcome measure that assesses health-related quality of life across five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each rated on a 5-level scale (no problems to extreme problems). The score is calculated using a country-specific value set to produce a single index value ranging from -0.594 (worse than death) to 1.0 (perfect health), where higher scores indicate better health status.

Countries

United States

Participant flow

Participants by arm

ArmCount
Exposure to White LED Light and Crossover to Green LED Light.
Subjects will exposed to white light provided to them, in their homes in a dark room for approximately 2 hours for 10 weeks Exposure to white LED light: Participants will be exposed to white LED strip lights in a dark room for 2 hours a day. Subjects will exposed to green light provided to them, in their homes in a dark room for approximately 2 hours for 10 weeks. Exposure to green LED light: Participants will be exposed to green LED strip lights in a dark room for 2 hours a day. Subject will be exposed to white light (sham) for 10 weeks, then have a wash out period for 2 weeks, then exposed to green light (experimental) for 10 weeks. Exposure to green LED light: Participants will be exposed to green LED strip lights in a dark room for 2 hours a day. Exposure to white LED light: Participants will be exposed to white LED strip lights in a dark room for 2 hours a day.
55
Total55

Baseline characteristics

CharacteristicExposure to White LED Light and Crossover to Green LED Light.
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
5 Participants
Age, Categorical
Between 18 and 65 years
50 Participants
Age, Continuous52.7 years
STANDARD_DEVIATION 2.95
Ethnicity (NIH/OMB)
Hispanic or Latino
16 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
39 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
0 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
55 Participants
Region of Enrollment
United States
55 participants
Sex: Female, Male
Female
53 Participants
Sex: Female, Male
Male
2 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 550 / 55
other
Total, other adverse events
0 / 550 / 55
serious
Total, serious adverse events
0 / 550 / 55

Outcome results

Primary

For Chronic Pain

Change in the intensity of chronic pain as measured by the Numerical Pain Scale (NPS). The NPS has a value ranging from 0 to 10 out of a maximum of 10. 0 means no pain. 10 means the most severe pain.

Time frame: baseline and 10 - 22 weeks, depending on study arm

Population: Adult patients with chronic pain

ArmMeasureValue (MEAN)Dispersion
Exposure to White LED LightFor Chronic Pain0.45 score on a scaleStandard Deviation 0.2
Green LED Light ExposureFor Chronic Pain3.7 score on a scaleStandard Deviation 0.4
Secondary

EQ-5D-5L

Change in health-related quality of life as measured by the EQ-5D-5L. The EQ-5D-5L is a standardized, patient-reported outcome measure that assesses health-related quality of life across five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each rated on a 5-level scale (no problems to extreme problems). The score is calculated using a country-specific value set to produce a single index value ranging from -0.594 (worse than death) to 1.0 (perfect health), where higher scores indicate better health status.

Time frame: baseline and 10 - 22 weeks, depending on study arm

ArmMeasureValue (MEAN)Dispersion
Exposure to White LED LightEQ-5D-5L0.13 score on a scaleStandard Deviation 0.03
Green LED Light ExposureEQ-5D-5L0.28 score on a scaleStandard Deviation 0.04
Secondary

Fibromyalgia Impact Questionnaire

Change in Fibromyalgia Impact Questionnaire (FIQ) total score. The FIQ is a validated, self-reported measure assessing physical functioning, work status, depression, anxiety, sleep, pain, stiffness, fatigue, and well-being over the past week. Scores range from 0 to 100, with higher scores indicating greater impairment.

Time frame: baseline and 10 - 22 weeks, depending on study arm

Population: patients with fibromyalgia

ArmMeasureValue (MEAN)Dispersion
Exposure to White LED LightFibromyalgia Impact Questionnaire10.43 score on a scaleStandard Deviation 3.46
Green LED Light ExposureFibromyalgia Impact Questionnaire28.92 score on a scaleStandard Deviation 4.32
Secondary

Headache Impact Test-6

Change in Headache Impact Test-6 (HIT-6) total score from baseline to 10-22 weeks. The HIT-6 is a 6-item questionnaire designed to assess the impact of headaches on daily life, including pain severity, disability, and emotional effects over the past 4 weeks. Scores range from 36 to 78, where 36-49 indicates little or no impact, 50-55 indicates some impact, 56-59 reflects substantial impact, and 60-78 indicates severe impact requiring intervention. A higher score indicates greater headache impact.

Time frame: baseline and 10 - 22 weeks, depending on study arm

ArmMeasureValue (MEAN)Dispersion
Exposure to White LED LightHeadache Impact Test-61.14 score on a scaleStandard Deviation 1.3
Green LED Light ExposureHeadache Impact Test-612.85 score on a scaleStandard Deviation 1.6

Source: ClinicalTrials.gov · Data processed: Feb 17, 2026